Guided Therapeutics, Inc.'s LightTouch Cervical Scan Detected Disease Up to Two Years Earlier Than Pap, HPV and Biopsy in FDA Pivotal Clinical Trial

LAS VEGAS--(BUSINESS WIRE)--Some Women with Significant Cervical Disease Could Have Been Diagnosed Up to two years earlier using the Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) LightTouch™ Cervical Scanner, according to results of a U.S. Food and Drug Administration (FDA) pivotal clinical trial being presented at the American Society for Colposcopy and Cervical Pathology biennial meeting.